AUTHORS
Chen Liang, Yi He, MD2, Yigeng Cao II, MD, PhD3, Rongli Zhang4, Aimin Pang5, Sizhou Feng6, Donglin Yang7, Erlie Jiang, MD8
AFFILIATIONS
1 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
7 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Background
Chronic graft-versus-host disease (cGVHD) constitutes a leading cause of late morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Belumosudil, a ROCK2 inhibitor with immunomodulatory and antifibrosis effects, has emerged as a promising therapeutic agent for cGVHD and is approved for the treatment of adult and pediatric patients 12 years of age and older with cGVHD after failure of at least two prior lines of systemic therapy.
Aims
The current study evaluated the real-world efficacy and safety of belumosudil as second or subsequent line of therapy for patients with steroid-resistant or steroid-dependent (SR/SD) cGVHD.
Method
Eligible patients were allo-HSCT recipients with SR/SD cGVHD , after receiving 1 to 4 prior lines of therapy (LOT). Patients received belumosudil tablets 200 mg QD orally. Data including patient baseline characteristics, allo-HSCT details, cGVHD features and clinical outcomes were collected from patients' electronic medical records between August 2020 and July 2026.
The primary end point was overall response rate (ORR) at 6 months after initiation of belumosudil, defined as the proportion of patients who achieved complete response (CR) or partial response (PR) ,according to the 2014 NIH Consensus Criteria. Secondary end points included organ-specific response rates, rate of glucocorticoid reduction, failure-free survival (FFS; defined as the interval between the start of belumosudil and the addition of a new cGVHD therapy, relapse, or NRM) , overall survival (OS) and adverse events.
Results
A total of 107 patients who received belumosudil as second or subsequent LOT were enrolled in this study. The median age was 38 years (range 17–70). Females comprised 32.7% (n = 32) of the cohort. Acute GVHD (aGVHD) occurred in 57.9% (n = 62) of patients before cGVHD onset.
Before belumosudil treatment, patients received a median of 2 (range 1–4) lines of systemic therapy for cGVHD. Unlike prospective clinical trials, in real-world settings, belumosudil tended to be administered as second- or third-line therapy (n=93), particularly in patients complicated with cytopenias and pulmonary bronchiolitis obliterans (BO). Forty-two patients (39.3%) had moderate cGVHD and sixty-five (60.7%) had severe cGVHD; 57.0% had involvement of ≥3 organs. Fifty-nine patients (55.1%) had pulmonary cGVHD ( score 1 (n=23), score 2 (n=16) and score 3 (n=19)). In 76.6% (n=82) of patients, belumosudil was started while they were receiving steroids, 48.6% (n=52) had previously received ruxolitinib.
Overall median follow-up was 12.9 (range 4.9–27.9) months. At the data cutoff, 59.8% (n=64) of patients remained on belumosudil treatment. The 6-month ORR was 49.5% (n=53, 95% confidence interval [CI], 40.0-59.1%), with 10.3% achieving complete response and 39.2% achieving partial response. Glucocorticoid dosage reduction or discontinuation was observed in 49/82 patients (59.8%). Organ-specific response rates were evaluated in 102 patients. The ORR was 57.1% for skin, 53.4% for the mouth , 53.3% for joints/fascia and 23.7% for pulmonary involvement. The 12-month FFS was 79.7% (95% CI 71.9-87.5%). The 2-year OS rate was 90.9% (95%CI 85.2-96.6%).
Forty-three patients received combination therapy with belumosudil and ruxolitinib. Among these patients, 34/43 (79.1%) presented with severe cGVHD, and the 6-month ORR was 34.9% (95% CI, 20.9-51.2%).
Belumosudil was well tolerated in the study cohort. The most common adverse event was pulmonary infections (22.4%, n=24). Non-infectious AEs included hypertension, nausea and elevated transaminases. Three patients discontinued treatment due to an adverse event. There were no drug-related deaths.
Conclusion
In summary, data from the study demonstrate that belumosudil is effective and well-tolerated in patients with SR/SD cGVHD. Therapeutic responses were documented across all involved organs and among patients with prior ruxolitinib exposure. Its limited toxicity together with encouraging survival outcomes renders it a favorable therapeutic option for this patient population.
DISCLOSURES
Chen Liang: No relevant conflicts of interest to declare.